Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.18
$0.46
$17.51
$978.01M-0.1390,307 shs22,300 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$28.30
-2.2%
$27.71
$17.82
$30.69
$2.06B0.05555,115 shs119,555 shs
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$26.98
$26.96
$7.67
$27.06
$2.62B2.171.17 million shs2.26 million shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$11.89
-1.2%
$10.61
$5.35
$16.15
$647.39M1.14672,425 shs145,711 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00%0.00%0.00%0.00%0.00%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+0.52%+3.93%-2.75%+49.92%+38.12%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00%0.00%0.00%0.00%0.00%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
+0.17%+4.83%+5.99%+71.51%-9.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.7922 of 5 stars
0.00.00.04.80.60.80.6
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.6167 of 5 stars
3.54.00.00.02.83.30.6
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.9195 of 5 stars
3.70.00.04.81.60.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00
N/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$39.3338.99% Upside
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00
N/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.33
Buy$24.75108.09% Upside

Current Analyst Ratings Breakdown

Latest STOK, KNSA, MYOV, FIXX, and CNTTF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.00
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $35.00
4/29/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $45.00
4/16/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.16M0.00N/AN/A$1.26 per share0.00
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$423.24M4.88N/AN/A$6.60 per share4.29
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$230.97M11.36N/AN/A($5.04) per share-5.35
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$36.56M17.76N/AN/A$4.32 per share2.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M-$0.25N/A113.20N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.7915.01N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)

Latest STOK, KNSA, MYOV, FIXX, and CNTTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.0905N/AN/AN/A$31.51 millionN/A
7/22/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.08N/AN/AN/AN/AN/A
4/29/2025Q1 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.02$0.11+$0.09$0.11$128.35 million$137.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/A
7.25
7.25
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.66
3.43
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/A
1.57
1.45
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
8.41
8.41
CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
758.13 million48.77 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22072.97 million33.95 millionOptionable
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
40797.24 million95.39 millionNot Optionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.60 million49.41 millionOptionable

Recent News About These Companies

Lille rival Aston Villa in race for Stoke’s Sol Sidibé
Aston Villa want Stoke City midfielder Sol Sidibe
Live updates after 'accident' on Stoke-on-Trent road
Stoke City close in on fourth summer signing
Live updates as firefighters on scene of Stoke-on-Trent blaze
Driver dies in Royal Stoke after hitting tree
DONE DEAL: Stoke snap up Man City striker Mubama
Mubama set for Stoke loan switch

New MarketBeat Followers Over Time

Media Sentiment Over Time

CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Homology Medicines stock logo

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.30 -0.65 (-2.25%)
As of 12:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Myovant Sciences stock logo

Myovant Sciences NYSE:MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$11.89 -0.15 (-1.21%)
As of 12:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.